Results 211 to 220 of about 488,286 (382)

Maximizing the Quality and Reporting Standards of Autism Intervention Science

Autism Research, EarlyView.
ABSTRACT Although there are clear international standards for intervention science and reporting in healthcare, implementation and uptake have been limited within autism intervention research. To address this concern, a Special Interest Group (SIG) was convened at the International Society for Autism Research (INSAR) Annual Meetings in May 2023 and May
Shannon LaPoint, Claire Brito Klein, Micheal Sandbank, Kristen Bottema‐Beutel, Sue Fletcher‐Watson, Gauri Divan, Dagmara Dimitriou, Evdokia Anagnostou, Mette Elmose Andersen, Amanda Binns, Tony Charman, Jasper A. Estabillo, Stephanie M. Fecteau, Anna Ferrari, Marie‐Maude Geoffray, Lauren H. Hampton, Sabri Hergüner, Emily S. Kuschner, Jia Ying Sarah Lee, Julie Segers, Deanna Swain, Sarah Vejnoska, Giacomo Vivanti, Chongying Wang, Jonathan Green   +24 more
wiley   +1 more source

A systematic qualitative review of ethical issues in open label placebo in published research. [PDF]

Sci Rep
Richard M, Bernstein M, Gaab J, Elger B.
europepmc   +1 more source

Placebo – Nocebo [PDF]

Kompass Onkologie, 2020
openaire   +5 more sources

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani, Braidon A. Lape, Anneliese M. Harp, Victoria Weisbrod, Lavinia Piazza   +4 more
wiley   +1 more source

Would You Take an Open-Label Placebo Pill or Give One to Your Child? Findings from a Cross-Sectional Survey

Psychology Research and Behavior Management
Anne Schienle, Arved Seibel Department of Clinical Psychology, University of Graz, Graz, AustriaCorrespondence: Anne Schienle, Email anne.schienle@uni-graz.atBackground: Open-label placebos (OLPs), honestly prescribed regarding their inert nature, have ...
Schienle A, Seibel A
doaj  

Public and professional attitudes towards deceptive and open-label placebo in functional neurological disorder and wider neurological practice. [PDF]

BMJ Neurol Open
Huys AML, Bhatia KP, Edwards MJ.
europepmc   +1 more source

A Placebo-Controlled Double-Blind Crossover Investigation of the Side Effects Attributed to Oral Contraceptives

, 1971
Joseph W. Goldzieher, Louis E. Moses, E. G. Averkin, Cora Scheel, Ben Z. Taber   +4 more
openalex   +1 more source

Hormonal and metabolic effects of chlorpropamide, glibenclamide and placebo in a cross-over study in diabetics not controlled by diet alone [PDF]

, 1981
Peter H. Sönksen, C. Lowy, J. R. Perkins, Tim West   +3 more
openalex   +1 more source

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Casdatifan is an orally bioavailable small‐molecule hypoxia‐inducible factor‐2α (HIF‐2α) inhibitor currently in development for treating patients with clear cell renal cell carcinomas. The aim of this study was to characterize the pharmacokinetics (PK), pharmacodynamics and safety of casdatifan in healthy participants.
Mohammad Ghasemi, Ji Yun Kim, Lisa Seitz, Lixia Jin, Paul G. Foster, Kai H. Liao, Tzuling Cheng, Elaine Paterson, Maria Velinova, Nicole Rivera Rosario, Reza Khosravan, Balaji Agoram   +11 more
wiley   +1 more source

Investigating whether socially acquired nocebo effects can spread to other treatments. [PDF]

Sci Rep
Saunders C, Tan W, Barnes K, McNair N, Colagiuri B.   +4 more
europepmc   +1 more source